SpringWorks Therapeutics (SWTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Key Insights
Critical company metrics and information
Share Price
$41.77Market Cap
$3.11 BillionTotal Outstanding Shares
74.39 Million SharesTotal Employees
305Dividend
No dividendIPO Date
September 13, 2019SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.springworkstx.com
Historical Stock Splits
If you bought 1 share of SWTX before March 17, 2011, you'd have 0.20 shares today.
Execution Date | Split Amount |
---|---|
March 17, 2011 | 1-for-5 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-14.43 Million |
Net Cash Flow From Financing Activities | $303.18 Million |
Net Cash Flow From Operating Activities, Continuing | $-208.80 Million |
Net Cash Flow From Investing Activities | $-108.81 Million |
Net Cash Flow From Operating Activities | $-208.80 Million |
Net Cash Flow From Investing Activities, Continuing | $-108.81 Million |
Net Cash Flow, Continuing | $-14.43 Million |
Net Cash Flow From Financing Activities, Continuing | $303.18 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Basic Average Shares | $148.95 Million |
Net Income/Loss | $-275.16 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Parent | $-275.16 Million |
Research and Development | $183.93 Million |
Selling, General, and Administrative Expenses | $239.39 Million |
Basic Earnings Per Share | $-3.89 |
Operating Income/Loss | $-295.25 Million |
Income/Loss From Continuing Operations After Tax | $-275.16 Million |
Income/Loss From Continuing Operations Before Tax | $17.81 Million |
Operating Expenses | $423.32 Million |
Diluted Average Shares | $148.95 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income/Loss From Equity Method Investments | $-6.45 Million |
Income/Loss Before Equity Method Investments | $-90.68 Million |
Nonoperating Income/Loss | $26.54 Million |
Revenues | $135.49 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-275.16 Million |
Diluted Earnings Per Share | $-3.89 |
Cost Of Revenue | $7.42 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $70.61 Million |
Other Non-current Assets | $154.43 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $435.11 Million |
Assets | $608.88 Million |
Liabilities | $76.30 Million |
Cash | $498.10 Million |
Accounts Payable | $9.65 Million |
Noncurrent Assets | $173.77 Million |
Fixed Assets | $19.34 Million |
Noncurrent Liabilities | $5.68 Million |
Liabilities And Equity | $608.88 Million |
Equity | $532.58 Million |
Wages | $20.31 Million |
Equity Attributable To Parent | $532.58 Million |
Inventory | $9.83 Million |
Other Current Liabilities | $40.65 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.